Europe
Completion of multi-million Euro expansion of manufacturing capacity and deployment of next generation production technologies
Recipharm, a leading contract development and manufacturing organisation (CDMO), has released its first serialised products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden.
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
New late-stage data released by Janssen shows that a single dose of Stelara can induce clinical reemission and response in adult patients with moderate to severe ulcerative colitis who have not had positive response from previous treatment options.
Kenneth Frazier, chief executive officer of Merck, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.
In looking at companies that are shaping the future, Time Magazine selected 50 business that are leading the charge. While many tech companies lead the way, there are several pharma and life science companies that are also disrupting the future.
Affimed, based in Heidelberg, Germany, placed a clinical hold on its two AFM11 Phase I clinical trials. AFM11 is being evaluated in the trials for relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia.
eTheRNA immunotherapies announces the opening of a state-of-the-art mRNA manufacturing facility enabling the production of mRNA immunotherapies.
PRESS RELEASES